You just read:

Sorrento Therapeutics anti-CEA CAR-T Demonstrates Promising Clinical Activity and Safety in Phase Ib Clinical Trial

News provided by

Sorrento Therapeutics, Inc.

Apr 03, 2017, 13:25 ET